Last reviewed · How we verify
Placebo for Linaclotide
This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action.
This is a placebo control, containing no active pharmaceutical ingredient and therefore has no mechanistic action. Used for Control arm in linaclotide clinical trials (Phase 3).
At a glance
| Generic name | Placebo for Linaclotide |
|---|---|
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of the active drug (linaclotide) through comparison. It produces no pharmacological effect and serves only as a comparator to distinguish true drug effects from natural disease progression or placebo response.
Approved indications
- Control arm in linaclotide clinical trials (Phase 3)
Common side effects
Key clinical trials
- A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide (PHASE2)
- A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation (PHASE3)
- Clinical Study of Bowel Preparation Before Colonoscopy (NA)
- Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) (PHASE3)
- A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation (PHASE3)
- Application of Linaclotide Capsule in Bowel Preparation for Patients at High Risk of Inadequate Bowel Preparation (NA)
- Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation (PHASE4)
- Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Linaclotide CI brief — competitive landscape report
- Placebo for Linaclotide updates RSS · CI watch RSS
- AbbVie portfolio CI